19-nor-5β-androstane-3,17-dione | 5696-51-5

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 19-nor-5β-androstane-3,17-dione
• 英文别名: 5β-Oestran-3,17-dion；19-Nor-5β-androstan-3,17-dion；19-Nor-5β-androstandion-3,17；(5R,10S,13S)-13-methyl-1,2,4,5,6,7,8,9,10,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,17-dione
• CAS: 5696-51-5
• 化学式: C₁₈H₂₆O₂
• 分子量: 274.403
• InChiKey: CRDKSBHJIGNEOH-WTQSVHAMSA-N

物化性质

• 熔点：
  179-181 °C
• 沸点：
  411.2±45.0 °C(Predicted)
• 密度：
  1.087±0.06 g/cm3(Predicted)
• 溶解度：
  溶于DCM、乙酸乙酯、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  19-nor-androst-4-ene-3,17-dione 在 钯 氢溴酸 、 氢气 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以77%的产率得到19-nor-5β-androstane-3,17-dione
  参考文献：
  名称：

  Highly stereoselective hydrogenation of 3-oxo-4-ene and -1,4-diene steroids to 5.beta. compounds with palladium catalyst

  摘要：

  DOI：

  10.1021/jo01301a043

文献信息

• [EN] 3,3 DISUBSTITUTED 19-NOR PREGNANE COMPOUNDS, COMPOSITIONS, AND USES THEREOF<br/>[FR] COMPOSÉS 19-NOR-PRÉGNANE 3,3-DISUBSTITUÉS, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2013056181A1

  公开（公告）日：2013-04-18

  Provided herein are 3,3-disubstituted 19-nor- steroidal compounds according to Formula (I) and (III): where R1,R2, R3, R3', R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.

  根据公式（I）和（III），提供了3,3-二取代19-去甲类固醇化合物：其中R1、R2、R3、R3'、R4、R6a、R6a、R11a和R11b如本文所定义。本发明的化合物被认为对预防和治疗各种与中枢神经系统相关的疾病有用，例如治疗睡眠障碍、情绪障碍、失眠、焦虑、抑郁、创伤性脑损伤（TBI）、压力和癫痫。
• 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
  申请人：Sage Therapeutics, Inc.

  公开号：US10435431B2

  公开（公告）日：2019-10-08

  Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I) and (III): where R1, R2, R3, R3′, R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.

  本文提供的是符合式（I）和式（III）的 3,3-二取代 19-去甲甾体化合物： 其中R1、R2、R3、R3′、R4、R6a、R6a、R11a和R11b如本文所定义。本发明的化合物可用于预防和治疗各种中枢神经系统相关疾病，例如治疗睡眠障碍、情绪障碍、失眠、焦虑、抑郁、创伤性脑损伤（TBI）、压力和癫痫。
• 3,3 DISUBSTITUTED 19-NOR PREGNANE COMPOUNDS, COMPOSITIONS, AND USES THEREOF
  申请人：SAGE THERAPEUTICS, INC.

  公开号：US20150291654A1

  公开（公告）日：2015-10-15

  Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I) and (III): where R 1 , R 2 , R 3 , R 3′ , R 4 , R 6a , R 6a , R 11a , and R 11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.
• Highly stereoselective hydrogenation of 3-oxo-4-ene and -1,4-diene steroids to 5.beta. compounds with palladium catalyst
  作者：Natsuko Tsuji、Jun Suzuki、Michio Shiota、Izumi Takahashi、Shigeo Nishimura

  DOI：10.1021/jo01301a043

  日期：1980.6